



- Creating Kansas jobs: 3 FT at >\$70K each, and 4 PT
- Bringing \$\$ into Kansas from California, Texas, Georgia, Missouri via Angel Credits
- Developing KU Intellectual Property so success will flow back into Kansas institutions
 - Winning \$300,000 National Cancer Institute 2015-16 SBIR (to be spent in Kansas at HylaPharm and KU)
 - Fighting cancer with Kansas research

HylaPharm is a KU spinout company developing new targeted cancer therapies. HylaPlat™ is a new cancer drug that has already shown efficacy in multiple mouse models of human cancers, and in several dogs with large, naturally occurring cancers. It is the first targeted chemotherapy for potentially deadly, locally advanced cancers that affect nearly 200,000 Americans. Unlike conventional chemotherapy that enters a vein and travels all around the body before getting to the tumor, HylaPlat™ is injected directly into the primary tumor, resulting in very high tumor penetration. HylaPlat™ then goes into local lymph nodes, where tumors generally metastasize first.

HylaPharm has an National Cancer Institute (NCI) small business SBIR contract to develop treatments for triple negative breast cancer, and HylaPlat™ has received FDA MUMS designation. Work toward human IND is in process.



This dog with confirmed nasal squamous cell carcinoma was able to avoid deforming surgery and radiation while achieving a complete response to the cancer:

